{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:13:27Z","timestamp":1789748007815,"version":"4.0.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200\u2009mg every 2\u2009weeks) monotherapy (MONARCH study) with that of sarilumab and MTX combination therapy (MOBILITY study) at week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The endpoints assessed were mean change from baseline in the Clinical Disease Activity Index (CDAI), 28-joint Disease Activity using CRP (DAS28-CRP), CRP, haemoglobin (Hb), pain visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)\u2013Fatigue. Least square (LS) mean change from baseline (95% CI) at week 24 for all endpoints was compared between the treatment arms for adjusted comparisons.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This analysis included 184 patients on sarilumab monotherapy and 399 patients on sarilumab plus MTX. Differences (P\u2009&amp;lt;\u20090.05) were observed in ethnicity, region, body mass index group, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, swollen joint count, CRP, CDAI and oral glucocorticoid use between these treatment groups. After adjusting for these differences in a mixed-effect model repeated measure, LS mean change from baseline for all assessments was similar between the treatment groups with overlapping CIs: CDAI, \u221228.79 vs \u221226.21; DAS28-CRP, \u22122.95 vs \u22122.81; CRP, \u221218.31 vs \u221216.46; Hb, 6.59 vs 8.09; Pain VAS, \u221233.62 vs \u221231.66; FACIT-Fatigue, 9.90 vs 10.24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This analysis demonstrated that the efficacy of sarilumab monotherapy was similar to that of sarilumab and MTX combination therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab676","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:35:28Z","timestamp":1631100928000},"page":"2596-2602","source":"Crossref","is-referenced-by-count":9,"title":["Sarilumab monotherapy <i>vs<\/i> sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2014University Medicine Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian P","family":"Bykerk","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Inflammatory Arthritis Center, Hospital for Special Surgery , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal & Dermatological Sciences, Centre for Musculoskeletal Research, Faculty of Biology, Medicine & Health, University of Manchester"},{"name":"NIHR Manchester Biomedical Research Centre , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Sanofi , Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"van Hoogstraten","sequence":"additional","affiliation":[{"name":"Department of, Global Medical Affairs, Sanofi , Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fernandez-Nebro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UGC Rheumatology, Institute of Biomedical Research in Malaga (IBIMA), Regional University Hospital of Malaga, University of M\u00e1laga , M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University , Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2022060107550680100_keab676-B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41927-019-0090-7","article-title":"A systematic review of guidelines for managing rheumatoid arthritis","volume":"3","author":"Mian","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2022060107550680100_keab676-B2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022060107550680100_keab676-B3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/acr2.11079","article-title":"Real-world adherence to oral methotrexate measured electonically in patients with established rheumatoid arthritis","volume":"1","author":"Michaud","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2022060107550680100_keab676-B4","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3899\/jrheum.151212","article-title":"Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review","volume":"43","author":"Curtis","year":"2016","journal-title":"J Rheumatol"},{"key":"2022060107550680100_keab676-B5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2022060107550680100_keab676-B6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/TCRM.S3470","article-title":"Interleukin-6 inhibitors in the treatment of rheumatoid arthritis","volume":"4","author":"Hennigan","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2022060107550680100_keab676-B7","article-title":"Role of interleukin 6 inhibitors in the management of rheumatoid arthritis","author":"Yip","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2022060107550680100_keab676-B8"},{"key":"2022060107550680100_keab676-B9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1060028018761599","article-title":"Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis","volume":"52","author":"Boyce","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2022060107550680100_keab676-B10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/PROM.S147286","article-title":"Sarilumab: patient-reported outcomes in rheumatoid arthritis","volume":"9","author":"Crotti","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"2022060107550680100_keab676-B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt-2017-0075","article-title":"A review of sarilumab for the treatment of rheumatoid arthritis","volume":"10","author":"Lee","year":"2018","journal-title":"Immunotherapy"},{"key":"2022060107550680100_keab676-B12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022060107550680100_keab676-B13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","article-title":"Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial","volume":"18","author":"Strand","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022060107550680100_keab676-B14"},{"key":"2022060107550680100_keab676-B15"},{"key":"2022060107550680100_keab676-B16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022060107550680100_keab676-B17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","article-title":"Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022060107550680100_keab676-B18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022060107550680100_keab676-B19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-014-2857-y","article-title":"Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice","volume":"34","author":"Bykerk","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2022060107550680100_keab676-B20","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2022060107550680100_keab676-B21","doi-asserted-by":"crossref","first-page":"e021447","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab676\/40434877\/keab676.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2596\/43891651\/keab676.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2596\/43891651\/keab676.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:56:52Z","timestamp":1654070212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2596\/6368708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,11]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab676","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,9,11]]}}}